A Phase 3 interventional study of S-217622 and Placebo in SARS-CoV-2 Infection, sponsored by Shionogi. Completed at 178 sites in 5 countries. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Shionogi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 76th largest by enrollment of the 1,321 interventional ones that give a count, is one of 131 that started in 2023, is one of 174 in phase 3, and was the 1,655th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 131 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,701 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Shionogi has 7 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (positive reverse transcription polymerase chain reaction [RT-PCR] test) and have coronavirus disease 2019 (COVID-19) symptom(s) with S-217622 tablets compared with placebo tablets in participants who are household contacts of an individual with symptomatic COVID-19.
This study will enroll 2 types of participants: 1. those with a negative screening SARS-CoV-2 infection (referred to as "study participants"); 2. those with a positive screening SARS-CoV-2-infection (referred to as "index participants"). Study participants will receive study intervention (S-217622 or placebo), index participants will receive no study intervention. A total of 3701 participants will be enrolled in the study, of whom 2387 will be randomized to receive study drug or placebo, and 1314 will be enrolled as index case participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Index Participants
Only 1 index participant from each household will be enrolled in the study. Participants are eligible to be included as an index participant if all of the following criteria apply:
The index participant must:
Study Participants
Multiple study participants from the same household are allowed to be enrolled in the study. The study intervention randomization will be performed based at the study participant's level. Participants will be eligible to be included in the study only if all of the following criteria apply:
Must not be considered by the investigator or subinvestigator to have SARS-CoV-2 infection and:
a. Male participants: Participants with partners that are woman of (WOCBP) must agree to use effective . Participants with pregnant partners must agree to use effective contraception.
b. Female participants: A female participant is eligible to participate if she is not pregnant or breastfeeding, and the following conditions applies:
All of the following apply:
Exclusion Criteria:
Study Participants: Participants will be excluded from the study if any of the following criteria apply:
Participants who have used any of the following drugs within 14 days prior to enrollment:
Note: Other protocol-defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
S-217622 will be administered orally for 5 days.
Drug: S-217622
Placebo matching to S-217622 will be administered orally for 5 days.
Drug: Placebo
Administered as a tablet.
Also known as: XOCOVA, ensitrelvir
Administered as a tablet.
Number of Participants in mITT Population Who Were Infected With SARS-CoV-2 and Had Coronavirus Disease 2019 (COVID-19) Symptoms Onset
Symptomatic COVID-19 was defined as a central laboratory-confirmed (CLC) positive reverse transcription polymerase chain reaction (RT-PCR) test and the occurrence (or worsening \[increasing a symptom score from baseline\] in the case of preexisting COVID-19-like symptoms) of \>= 1 of the 14 specified COVID-19 symptoms for at least 48 hours.
Time frame: Day 1 up to Day 10
Number of Participants in ITT Population With a Negative Screening SARS-CoV-2 Infection Who Were Infected With SARS-CoV-2 and Had COVID-19 Symptoms Onset
Symptomatic COVID-19 was defined as a CLC positive RT-PCR test and the occurrence (or worsening \[increasing a symptom score from baseline\] in the case of preexisting COVID-19-like symptoms) of \>= 1 of the 14 specified COVID-19 symptoms for at least 48 hours.
Time frame: Day 1 up to Day 10
Number of Participants Infected With SARS-CoV-2 Regardless of Occurrence of COVID-19 Symptoms
COVID-19 with or without symptoms onset was defined as any post baseline CLC-positive RT-PCR test.
Time frame: Days 10, 15 and 28
Time to the First Central Laboratory Confirmed-Positive Reverse Transcription Polymerase Chain Reaction Result
Time frame: Day 1 up to Day 28
Number of Participants With a Central Laboratory Confirmed-Positive Reverse Transcription Polymerase Chain Reaction Results
Time frame: Day 1 up to Day 10
Number of Participants Infected With SARS-CoV-2 With no COVID-19 Symptoms at Day 10
Asymptomatic COVID-19 was defined as: Incident SARS-CoV-2 infection between first study intervention administration and Day 10 visit, as confirmed by CLC positive RT-PCR test, no negative RT-PCR test between (1) the day of the first positive test and (2) Day 10 visit after the first study intervention and no COVID-19 symptoms occurrence on Day 10 (or if Day 10 is missing, no symptoms recorded on the most recent diary entry prior to Day 10).
Time frame: Day 10
Number of Participants Infected With SARS-CoV-2 and Had no COVID-19 Symptoms Onset Through Day 10
COVID-19 without symptoms onset was defined as any post-baseline CLC positive RT-PCR result through the Day 10 visit (up to day 11), but without any new or worsening symptoms having duration \>=48 hours starting by day 10.
Time frame: Day 1 up to Day 10
Number of Participants With Sustained Symptom Resolution of Each COVID-19 Symptoms
Sustained symptoms resolution was defined as \>=48 hours with each symptom (except loss of taste and loss of smell) having an equal or lower symptom score relative to that symptom's baseline value.
Time frame: Day 1 up to Day 28
Change From Baseline in Total Symptom Score of COVID-19 Symptoms at Day 10
Total symptom score was defined as the sum of scores for all 14 targeted symptoms (each individual symptom score was 0 = none, 1 = mild, 2 = moderate, and 3 = severe), where total score ranged 0 (none)-42 (severe symptom) and higher scores indicated severe symptoms.
Time frame: Baseline, Day 10
Time From First Central Laboratory Confirmed SARS-CoV-2 Until at Least 1 COVID-19 Symptom
Time from CLC positive RT-PCR test to time of first symptoms diary reporting at least 1 COVID-19 symptom with greater-than-baseline severity through Day 28 has been reported.
Time frame: Day 1 up to Day 28
Time From First Central Laboratory Confirmed SARS-CoV-2 Until COVID-19 Symptoms Onset
COVID-19 symptoms onset was defined as the occurrence (or worsening \[increasing a symptom score from baseline\] in the case of preexisting COVID-19-like symptoms) of \>= 1 of the 14 specified COVID-19 symptoms for at least 48 hours.
Time frame: Day 1 up to Day 28
Number of Participants Experiencing Hospitalization or Death From Any Cause
Hospitalization was defined as \>=24 hours of acute care for any reason, in a hospital or similar acute care facility, including emergency rooms or urgent care clinics. The participants reported below were hospitalized. No participants died in the study.
Time frame: Day 1 up to Day 28
Trough Concentration (Ctrough) of S-217622
Time frame: Day 3
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. A TEAE was defined as an AE reported after the first dose of study intervention. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Day 1 up to Day 28
| Milestone | S-217622 | Placebo | Index Case Participants |
|---|---|---|---|
| Started | 1194 | 1193 | 1314 |
| Received at least 1 dose of study drug | 1190 | 1187 | 0 |
| Modified intention-to-treat (mitt) analysis set | 1030 | 1011 | 0 |
| Intent to treat (itt) | 1194 | 1193 | 0 |
| Completed | 1172 | 1158 | 1314 |
| Not completed | 22 | 35 | 0 |
| Withdrew: Other than specified | 3 | 1 | 0 |
| Withdrew: Lost to follow-up | 6 | 7 | 0 |
| Withdrew: Withdrawal by subject | 12 | 25 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Failure to meet eligibility criteria | 1 | 0 | 0 |
Symptomatic COVID-19 was defined as a central laboratory-confirmed (CLC) positive reverse transcription polymerase chain reaction (RT-PCR) test and the occurrence (or worsening \[increasing a symptom score from baseline\] in the case of preexisting COVID-19-like symptoms) of \>= 1 of the 14 specified COVID-19 symptoms for at least 48 hours.
| Participants | S-217622 | Placebo |
|---|---|---|
| Number of Participants in mITT Population Who Were Infected With SARS-CoV-2 and Had Coronavirus Disease 2019 (COVID-19) Symptoms Onset | 30 | 91 |
Symptomatic COVID-19 was defined as a CLC positive RT-PCR test and the occurrence (or worsening \[increasing a symptom score from baseline\] in the case of preexisting COVID-19-like symptoms) of \>= 1 of the 14 specified COVID-19 symptoms for at least 48 hours.
| Participants | S-217622 | Placebo |
|---|---|---|
| Number of Participants in ITT Population With a Negative Screening SARS-CoV-2 Infection Who Were Infected With SARS-CoV-2 and Had COVID-19 Symptoms Onset | 52 | 122 |
COVID-19 with or without symptoms onset was defined as any post baseline CLC-positive RT-PCR test.
| Participants | S-217622 | Placebo |
|---|---|---|
| Day 10 | 144 | 217 |
| Day 15 | 183 | 261 |
| Day 28 | 253 | 318 |
| hours | S-217622 | Placebo |
|---|---|---|
| Time to the First Central Laboratory Confirmed-Positive Reverse Transcription Polymerase Chain Reaction Result | 613.70 ± 7.845 | 558.26 ± 9.672 |
| Participants | S-217622 | Placebo |
|---|---|---|
| Number of Participants With a Central Laboratory Confirmed-Positive Reverse Transcription Polymerase Chain Reaction Results | 56 | 131 |
Asymptomatic COVID-19 was defined as: Incident SARS-CoV-2 infection between first study intervention administration and Day 10 visit, as confirmed by CLC positive RT-PCR test, no negative RT-PCR test between (1) the day of the first positive test and (2) Day 10 visit after the first study intervention and no COVID-19 symptoms occurrence on Day 10 (or if Day 10 is missing, no symptoms recorded on the most recent diary entry prior to Day 10).
| Participants | S-217622 | Placebo |
|---|---|---|
| Number of Participants Infected With SARS-CoV-2 With no COVID-19 Symptoms at Day 10 | 41 | 69 |
COVID-19 without symptoms onset was defined as any post-baseline CLC positive RT-PCR result through the Day 10 visit (up to day 11), but without any new or worsening symptoms having duration \>=48 hours starting by day 10.
| Participants | S-217622 | Placebo |
|---|---|---|
| Number of Participants Infected With SARS-CoV-2 and Had no COVID-19 Symptoms Onset Through Day 10 | 118 | 133 |
Sustained symptoms resolution was defined as \>=48 hours with each symptom (except loss of taste and loss of smell) having an equal or lower symptom score relative to that symptom's baseline value.
| Participants | S-217622 | Placebo |
|---|---|---|
| Number of Participants With Sustained Symptom Resolution of Each COVID-19 Symptoms | 19 | 58 |
Total symptom score was defined as the sum of scores for all 14 targeted symptoms (each individual symptom score was 0 = none, 1 = mild, 2 = moderate, and 3 = severe), where total score ranged 0 (none)-42 (severe symptom) and higher scores indicated severe symptoms.
| scores on a scale | S-217622 | Placebo |
|---|---|---|
| Change From Baseline in Total Symptom Score of COVID-19 Symptoms at Day 10 | 0.07 ± 0.525 | 0.26 ± 1.318 |
Time from CLC positive RT-PCR test to time of first symptoms diary reporting at least 1 COVID-19 symptom with greater-than-baseline severity through Day 28 has been reported.
| hours | S-217622 | Placebo |
|---|---|---|
| Time From First Central Laboratory Confirmed SARS-CoV-2 Until at Least 1 COVID-19 Symptom | 464.98 ± 19.863 | 390.74 ± 19.557 |
COVID-19 symptoms onset was defined as the occurrence (or worsening \[increasing a symptom score from baseline\] in the case of preexisting COVID-19-like symptoms) of \>= 1 of the 14 specified COVID-19 symptoms for at least 48 hours.
| hours | S-217622 | Placebo |
|---|---|---|
| Time From First Central Laboratory Confirmed SARS-CoV-2 Until COVID-19 Symptoms Onset | 495.69 ± 18.616 | 394.89 ± 19.525 |
Hospitalization was defined as \>=24 hours of acute care for any reason, in a hospital or similar acute care facility, including emergency rooms or urgent care clinics. The participants reported below were hospitalized. No participants died in the study.
| Participants | S-217622 | Placebo |
|---|---|---|
| Number of Participants Experiencing Hospitalization or Death From Any Cause | 2 | 0 |
| microgram/milliliters | S-217622 |
|---|---|
| Trough Concentration (Ctrough) of S-217622 | 12.802 ± 61.4 |
An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. A TEAE was defined as an AE reported after the first dose of study intervention. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | S-217622 | Placebo |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 180 | 184 |
Collected over Day 1 up to Day 28. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| S-217622 | 0/1,190 (0%) | 3/1,190 (0.3%) | 0/1,190 (0%) |
| Placebo | 0/1,187 (0%) | 2/1,187 (0.2%) | 0/1,187 (0%) |
| Event | S-217622 | Placebo |
|---|---|---|
| ColitisGastrointestinal disorders | 0/1190 | 1/1187 |
| Hepatic enzyme increasedInvestigations | 0/1190 | 1/1187 |
| Umbilical HerniaGastrointestinal disorders | 1/1190 | 0/1187 |
| PneumoniaInfections and infestations | 1/1190 | 0/1187 |
| Urinary Tract InfectionInfections and infestations | 1/1190 | 0/1187 |
Randomized HHC participants: Safety analysis set included all participants randomly assigned to study intervention who received at least 1 dose of study intervention. Index case participants: All index participants who had met all eligibility requirements with a signed informed consent and were associated with 1 or more participants who were randomized to receive a study intervention and who did not have any exclusionary deviations.
| Age, Categorical(Participants) | S-217622 | Placebo | Index Case Participants | Total |
|---|---|---|---|---|
| <=18 years | 72 | 67 | 212 | 351 |
| Between 18 and 65 years | 1004 | 1002 | 965 | 2971 |
| >=65 years | 114 | 118 | 137 | 369 |
| Sex: Female, Male(Participants) | S-217622 | Placebo | Index Case Participants | Total |
|---|---|---|---|---|
| Female | 685 | 730 | 738 | 2153 |
| Male | 505 | 457 | 576 | 1538 |
| Ethnicity (NIH/OMB)(Participants) | S-217622 | Placebo | Index Case Participants | Total |
|---|---|---|---|---|
| Hispanic or Latino | 708 | 715 | 620 | 2043 |
| Not Hispanic or Latino | 482 | 472 | 694 | 1648 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | S-217622 | Placebo | Index Case Participants | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 3 | 4 | 2 | 9 |
| Asian | 376 | 376 | 573 | 1325 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 60 | 63 | 67 | 190 |
| White | 728 | 723 | 652 | 2103 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 23 | 21 | 19 | 63 |
Showing the first 100 of 178 sites across 5 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2023 to primary completion in Aug 2024, 14 months.
Results were first posted in Sep 2026, 2 years after primary completion. A results delay was requested in Aug 2025.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 14 months is above that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ensitrelvir